Anterogen Co (XKRX:065660) Net Income (Continuing Operations) : ₩-3,450 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Anterogen Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Anterogen Co's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was ₩-571 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-3,450 Mil.

Anterogen Co Net Income (Continuing Operations) Historical Data

The historical data trend for Anterogen Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anterogen Co Net Income (Continuing Operations) Chart

Anterogen Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-4,049.85

-4,375.06

-553.98

-6,837.10

-2,840.85

Anterogen Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															37.36	-1,653.70	-1,033.86	-190.64	-571.46

Anterogen Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,450 Mil.

Anterogen Co (XKRX:065660) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Anterogen Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Anterogen Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Anterogen Co (XKRX:065660) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anterogen Co Ltd (XKRX:065660) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Namsung Plaza, Gasan-dong, 405, 130, Digital-ro, Geumcheon-gu, Seoul, KOR, 08589

Website

http://www.anterogen.com

Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.

Anterogen Co (XKRX:065660) Headlines

No Headlines